Overview

Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel

Status:
COMPLETED
Trial end date:
2024-09-19
Target enrollment:
Participant gender:
Summary
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
Phase:
PHASE2
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd